Poison in
Plain Sight

Walk into any American home and you will find them. They are in the non-stick pan on your stove, the soft vinyl shower curtain, the pressed-wood cabinet under your sink, the scented laundry detergent, and the flame-retardant foam cushion you're sitting on right now. They are called endocrine-disrupting chemicals — and according to a growing chorus of some of the world's most credentialed researchers, physicians, and attorneys, they are quietly reshaping human health at a biological level most people never see coming.

Over the past several months, I have spoken with epidemiologists, toxicologists, and environmental lawyers. I have reviewed internal corporate documents, lobbying disclosures, congressional testimony, and decades of peer-reviewed science. The picture that emerges is not a conspiracy theory. It is a documented, methodical pattern of industrial production, regulatory capture, and coordinated suppression of inconvenient science — one that has been playing out for the better part of a century.

This is that story.

The list of chemicals found in ordinary household products that carry some form of cancer or endocrine concern is not short. It has been compiled over decades through the work of bodies like the International Agency for Research on Cancer (IARC), the National Institutes of Environmental Health Sciences (NIEHS), and hundreds of independent peer-reviewed studies.

What makes this problem particularly insidious is a principle that scientists have been trying to dislodge from regulatory thinking for decades: the traditional assumption that "the dose makes the poison." That is, that a substance is only dangerous in high quantities. For endocrine-disrupting chemicals, science now tells us this is wrong.

Dr. Sara Brosché, science advisor at IPEN, has stated plainly that even very low doses of endocrine-disrupting chemicals can cause health problems — and there may be no safe dose at all for some exposures, particularly during fetal development and early childhood. This is not a fringe position. It is the consensus of multiple international medical organizations.

The scientific alarm bells on toxic household chemicals have been ringing for decades. But it is only in recent years — as data accumulates and researchers go public in unprecedented numbers — that the public has started to hear them. I reached out to several of the leading voices in this field.

Their concern is shared by the most authoritative bodies in medicine. The Endocrine Society, the American Medical Association, the American Public Health Association, the Royal College of Obstetricians and Gynaecologists, the American College of Obstetrics and Gynecology, and the American Society of Reproductive Medicine have all issued formal statements calling for greater control and study of endocrine-disrupting chemicals. Their consensus is not ambiguous: regulation has failed to keep pace with science, and people are being harmed.

No investigation of toxic chemicals in American life is complete without a reckoning with Monsanto — the Missouri-based chemical and agricultural company that, before its 2018 acquisition by German pharmaceutical giant Bayer, spent more than a century producing some of the most consequential toxic substances ever manufactured.

Founded in 1901, Monsanto manufactured saccharin, then aspirin, then sulfuric acid, then plastics, and then, starting in 1935, polychlorinated biphenyls — PCBs — at its plant in Anniston, Alabama. PCBs are now recognized as persistent environmental pollutants that cause cancer, developmental damage, and neurological harm. They were banned in the US under the Toxic Substances Control Act in 1979. But the company knew about their dangers far earlier.

Documents produced during litigation showed that Monsanto knew PCBs were toxic. Company salesmen were internally warned to stay clear of the chemicals. That information never reached the Black workers at the Anniston plant — many of them descended from slaves and sharecroppers — who handled these substances without protective equipment for decades. The contamination in Anniston was so severe that some residents had PCB levels in their blood hundreds or thousands of times the average.

After divesting its chemical liabilities by spinning off a subsidiary called Solutia — which subsequently filed for bankruptcy under the weight of Monsanto's inherited debts — the company reinvented itself as an agricultural biotechnology firm. The vehicle for that reinvention was a herbicide called Roundup, whose active ingredient is glyphosate.

In 2015, the World Health Organization's International Agency for Research on Cancer classified glyphosate as a "probable human carcinogen," based primarily on peer-reviewed scientific literature. The EPA, relying heavily on unpublished regulatory studies submitted by Monsanto and its allies, reached the opposite conclusion in 2016, declaring glyphosate "not likely to be carcinogenic to humans." Internal company emails later revealed by plaintiffs' attorneys showed a Monsanto employee explicitly stating that keeping company employees off published studies was done to "help enhance credibility." The EPA said one thing. The world's premier cancer research agency said another. The gap between those two positions is worth examining carefully.

Internal Monsanto emails — released publicly through litigation and referred to as the "Monsanto Papers" — also reveal the company described its regulatory approach as "Freedom to Operate," defined as "the set of regulatory, technical, marketing, and communication actions to set up a more favorable environment to secure authorizations." The company is now facing a proposed $7.25 billion settlement for non-Hodgkin lymphoma claims in its latest round of Roundup litigation, with approximately 65,000 cases still pending as of 2026.

Monsanto's relationship with the federal government was never at arm's length. The company pioneered a practice now common across the chemical industry: placing its own executives into regulatory positions and pulling regulators back out into industry roles. This "revolving door" wasn't incidental. It was structural.

The chemical industry's approach to inconvenient regulation is well-documented and methodical. It borrows from the playbook that tobacco companies used for decades: fund industry-friendly research, attack independent scientists, flood regulatory agencies with comments and procedural delays, and spend liberally on the political figures who oversee those agencies.

The PFAS crisis is the most recent and perhaps starkest example. Per- and polyfluoroalkyl substances — "forever chemicals" that now contaminate the blood of virtually every American — have been known to be problematic since at least the 1980s. DuPont, then a primary PFAS manufacturer, sampled public drinking water supplies in Ohio and West Virginia in 1984 and found that PFOA was already contaminating them. The communities were not told. It would take attorney Robert Bilott, starting in 2001, to force that information into the open.

The revolving door spins in both directions. As of 2025, the Trump EPA contained multiple former PFAS industry figures in key positions: David Fotouhi, EPA Deputy Administrator, spent years defending corporate PFAS polluters accused of Clean Air Act violations. Nancy Beck, senior EPA adviser on chemical safety, had previously been director of the American Chemistry Council — and in a prior EPA role, actively worked to weaken restrictions on PFAS in products. Lynn Dekleva, responsible for greenlighting new chemicals for market, worked at DuPont for more than 30 years and came through the American Chemistry Council.

Meanwhile, the same administration moved to roll back the Biden EPA's 2024 rules limiting six PFAS chemicals in drinking water — regulations that public health officials described as the most significant protective step taken in decades. Those rules are now in legal jeopardy.

The 1976 Toxic Substances Control Act, the foundational law governing chemical regulation, was largely toothless for four decades. By the 1990s it had regulated fewer than ten of the more than 62,000 chemicals in commercial use. The 2016 Lautenberg Act expanded the EPA's powers, but the American Chemistry Council described it as a "watershed moment" primarily because its industry-friendly implementation allowed companies to continue introducing chemicals while review processes stretched on for years.

The landscape is not uniformly bleak. Against the well-funded machinery of the chemical lobby, a determined set of researchers, attorneys, and advocates have been mounting an increasingly effective counter-effort — one built on patient science, creative litigation, and the relentless work of getting accurate information to the public.

It is worth noting that the EU has banned or severely restricted more than 1,000 chemicals from personal care products alone. The United States has banned eleven. This disparity is not accidental — it reflects the different regulatory philosophies on either side of the Atlantic. The EU operates on a precautionary principle: if there is credible evidence of harm, the burden of proof falls on manufacturers to demonstrate safety. In the US, the opposite has historically been true. Chemicals are presumed safe until proven otherwise — a standard that, given the pace of regulatory review and the resources of the industry lobby, often means they are never proven otherwise at all.

The chemical lobby would prefer you feel powerless. You are not. While systemic change requires political will at scale, there are meaningful steps individuals and families can take right now to reduce their body burden of these substances — and collective consumer pressure has, historically, forced industry change faster than regulation ever did.

The Global Plastics Treaty, currently under negotiation among world leaders, represents one of the most significant opportunities in decades to regulate bisphenols, PFAS, and phthalates in plastic products at an international level. Civil society organizations are pushing for an ambitious treaty that would ban these chemicals in toys, children's items, and food-contact materials. Whether it succeeds will depend partly on whether citizens in enough countries signal that they want it.

The science is no longer in dispute. The chemicals are real. The harms are documented. What remains is the political question: whose voices will be louder — the $110 million lobbying arsenal of the chemical industry, or the communities, the scientists, the lawyers, and the people who simply want to live in homes that do not quietly hurt them.

That question, ultimately, is answered by all of us.